UCLA study reveals how autism-risk gene rewires the brain
Many gene variants have been linked to autism, but how do these subtle changes alter the brain, and ultimately behavior? Using a blend of brain imaging and genetic detective work, scientists at UCLA's David Geffen School of Medicine and Semel Institute for Neuroscience and Human Behavior are the first to illustrate how a gene variant tied to autism rewires the brain. Published in the Nov. 3 online edition of the journal Science Translational Medicine, their discovery pinpoints the crucial missing mechanism that links altered genes to modified brain function and disrupted learning.
"This is a key piece of the puzzle we've been searching for," said co-principal investigator Dr. Daniel Geschwind, a professor of neurology and psychiatry who holds UCLA's Gordon and Virginia MacDonald Distinguished Chair in Human Genetics. "Now we can begin to unravel the mystery of how genes rearrange the brain's circuitry, not only in autism but in many related neurological disorders."
The UCLA team scrutinized the differences in brain connectivity and function that result from two forms of the CNTNAP2 gene, one of which boosts the risk of autism.
Earlier studies by Geschwind and others demonstrated that the gene is most active during brain development in the frontal lobe. The region is highly involved in learning, which is often disrupted in autistic children. Suspecting that CNTNAP2 might influence brain activity, the researchers used functional magnetic resonance imaging (fMRI) to scan the brains of 32 children as they performed learning-related tasks. Half of the children had autism, and half did not. The team's goal was to measure the strength of various communication pathways in different regions of the brain as they connected with each other.
The fMRI images excited the scientists — and confirmed their suspicions. Regardless of their diagnosis, the children carrying the risk variant showed a disjointed brain. The frontal lobe was over-connected to itself and poorly connected to the rest of the brain. Communication with the back of the brain was particularly diminished. "In children who carry the risk gene, the front of the brain appears to talk mostly with itself," said the study's first author, Ashley Scott-Van Zeeland, who is now a Dickinson Research Fellow at the Scripps Translational Science Institute. "It doesn't communicate as much with other parts of the brain and lacks long-range connections to the back of the brain."
Depending on which CNTNAP2 version the child carried, the researchers also observed a difference in connectivity between the left and right sides of the brain. In most people, the left side processes functions tied to language, like speech and understanding. In the children with the non-risk gene, communication pathways in the frontal lobe linked more strongly to the left side of the brain. In children with the risk variant, communications pathways in the front lobe connected more broadly to both sides of the brain. The unusual symmetry suggests that the gene variant rewires connections in the brain, perhaps explaining why this version of CNTNAP2 is associated with delayed speech.
"We saw that if you had the risk variant, your brain showed disrupted activation patterns whether you were diagnosed on the autism spectrum or not," said co-principal investigator Susan Bookheimer, a professor of psychiatry who holds UCLA's Joaquin Fuster Chair in Cognitive Neurosciences. "We suspect that CNTNAP2 plays an important role in wiring neurons at the front of the brain and that the risk variant interferes with that process."
By enhancing understanding of the relationship between genes, the brain and behavior, the UCLA finding could lead to earlier detection for autism and new interventions to strengthen connections between the frontal lobe and the left side of the brain. "If we determine that the CNTNAP2 variant is a consistent predictor of language difficulties," said Scott-Van Zeeland, "we could begin to design targeted therapies to help rebalance the brain and move it toward a path of more normal development." Researchers could test whether specific therapies actually change brain function by measuring the connectivity of patients before and after therapy, she added.
The authors emphasized that the patterns of connectivity found in the study still fall along the spectrum of normal gene variation. "One third of the population carries this variant in its DNA," Geschwind said. "It's important to remember that the gene variant alone doesn't cause autism, it just increases risk."
Led by the UCLA Autism Center of Excellence, the research was supported by grants from the National Institute of Child Health and Human Development, the National Alliance for Autism Research, the National Center for Research Resources, Autism Speaks, the Whitehall Foundation, and the Training Program in Neurobehavioral Genetics at UCLA, and by a National Research Service Award. Other UCLA co-authors included Ana Alvarez-Retuerto, Lisa Sonnenblick, Jeffrey Rudie, Dara Ghahremani, Jeanette Mumford, Russell Poldrack, Mirella Dapretto and Brett Abrahams, who is now at Albert Einstein College of Medicine.